InsiderTrades.com logo
⭕ [URGENT] Buy Alert just triggered
From Behind the Markets   |   Ad
My absolute favorite stock just hit a critical "buy now" trigger price.
Click here for the ticker >>>

Charles Mather, IV Biography and Net Worth

Director of Eyenovia
  • Phone
  • Email
  • Website


Mr. Mather has been a member of our Board of Directors since March 2018. Since October 2019, Mr. Mather has been Managing Director, Equity Capital Markets at Suntrust Robinson Humphrey, Inc. Prior to that, since March 2015, Mr. Mather has been Managing Director, Co-Head of Equity Capital Markets at BTIG, LLC. From December 2009 to February 2015, he was the Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott, LLC. Between May 2007 and September 2008, Mr. Mather was the head of the Structured Equity Group at Jefferies Group Inc. Prior to that, Mr. Mather held various senior investment banking positions at Cowen and Company, including as Co- Head of the Private Equity Group. Mr. Mather serves on the board Wentz LLC. Mr. Mather also served on the board of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) until February 2019 and The Finance Company of Pennsylvania until August 2017. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.

What is Charles E. Mather, IV's net worth?

The estimated net worth of Charles E. Mather, IV is at least $6,614.50 as of May 26th, 2023. Mr. Mather, IV owns 77,544 shares of Eyenovia stock worth more than $6,615 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Mather, IV may own. Learn More about Charles E. Mather, IV's net worth.

How do I contact Charles E. Mather, IV?

The corporate mailing address for Mr. Mather, IV and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Charles E. Mather, IV's contact information.

Has Charles E. Mather, IV been buying or selling shares of Eyenovia?

Charles E. Mather, IV has not been actively trading shares of Eyenovia within the last three months. Most recently, on Friday, May 26th, Charles E. Iv Mather bought 3,000 shares of Eyenovia stock. The stock was acquired at an average cost of $2.49 per share, with a total value of $7,470.00. Following the completion of the transaction, the director now directly owns 77,544 shares of the company's stock, valued at $193,084.56. Learn More on Charles E. Mather, IV's trading history.

Who are Eyenovia's active insiders?

Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.

Are insiders buying or selling shares of Eyenovia?

In the last twelve months, Eyenovia insiders bought shares 6 times. They purchased a total of 1,752,939 shares worth more than $1,219,009.44. The most recent insider tranaction occured on August, 28th when CEO Michael M Rowe bought 27,071 shares worth more than $14,076.92. Insiders at Eyenovia own 7.1% of the company. Learn More about insider trades at Eyenovia.

Information on this page was last updated on 8/28/2024.

Charles E. Mather, IV Insider Trading History at Eyenovia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2023Buy3,000$2.49$7,470.0077,544View SEC Filing Icon  
5/18/2022Buy7,000$2.03$14,210.0048,322View SEC Filing Icon  
3/31/2022Buy4,000$3.12$12,480.00View SEC Filing Icon  
11/1/2021Buy4,000$3.83$15,320.00View SEC Filing Icon  
5/28/2021Buy3,000$4.76$14,280.0026,359View SEC Filing Icon  
9/19/2018Buy4,000$4.79$19,160.00View SEC Filing Icon  
See Full Table

Charles E. Mather, IV Buying and Selling Activity at Eyenovia

This chart shows Charles E Iv Mather's buying and selling at Eyenovia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eyenovia Company Overview

Eyenovia logo
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.09
Low: $0.08
High: $0.09

50 Day Range

MA: $0.29
Low: $0.08
High: $0.57

2 Week Range

Now: $0.09
Low: $0.08
High: $2.57

Volume

14,142,422 shs

Average Volume

3,200,527 shs

Market Capitalization

$7.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43
⭕ [URGENT] Buy Alert just triggered
From Behind the Markets   |   Ad
My absolute favorite stock just hit a critical "buy now" trigger price.
Click here for the ticker >>>